• Publications
  • Influence
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Integrase is essential for human immunodeficiency virus-type 1 (HIV-1) replication; however, potent inhibition of the isolated enzyme in biochemical assays has not readily translated into antiviralExpand
  • 1,035
  • 61
Genome-scale RNAi screen for host factors required for HIV replication.
Human immunodeficiency virus (HIV)-1 depends on the host cell machinery to support its replication. To discover cellular factors associated with HIV-1 replication, we conducted a genome-scale siRNAExpand
  • 750
  • 51
  • PDF
HIV-1 antiretroviral drug therapy.
  • E. Arts, D. Hazuda
  • Medicine
  • Cold Spring Harbor perspectives in medicine
  • 1 April 2012
The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiviral drugs, which can suppress HIV-1 replication to undetectable levels. TheExpand
  • 556
  • 47
  • PDF
Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro*
The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes. We demonstrate thatExpand
  • 300
  • 27
  • PDF
Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide Studies
We have analyzed host cell genes linked to HIV replication that were identified in nine genome-wide studies, including three independent siRNA screens. Overlaps among the siRNA screens were veryExpand
  • 438
  • 24
  • PDF
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
BACKGROUND We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1Expand
  • 518
  • 23
  • PDF
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
Histone deacetylases (HDACs) act on histones within the nucleosome-bound promoter of human immunodeficiency virus type 1 (HIV-1) to maintain proviral latency. HDAC inhibition leads to promoterExpand
  • 317
  • 21
  • PDF
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in theExpand
  • 512
  • 15
  • PDF
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important in maintainingExpand
  • 330
  • 15
  • PDF
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
ABSTRACT HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval asExpand
  • 213
  • 15
  • PDF